Actively Recruiting
Laparoscopic Versus Open Lower Mediastinal Lymphadenectomy for Esophagogastric Junction Cancer
Led by Peking University · Updated on 2021-12-02
1036
Participants Needed
1
Research Sites
308 weeks
Total Duration
On this page
Sponsors
P
Peking University
Lead Sponsor
P
Peking University Cancer Hospital & Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
Mediastinal lymph node dissection has been adopted as standard treatment for adenocarcinoma of esophagogastric junction(AEJ). This multi-center, exploratory, prospective, cohort study aims at provide standard technical details of laparoscopic mediastinal lymph node dissection, and explore the potential clinical effects, gather key information for following study regarding sample size calculation, primary outcome and feasibility.
CONDITIONS
Official Title
Laparoscopic Versus Open Lower Mediastinal Lymphadenectomy for Esophagogastric Junction Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years
- Karnofsky score of 70% or higher, or ECOG score of 2 or less
- Pathological biopsy confirming adenocarcinoma
- Tumor centered within 5cm above or below the esophagogastric junction crossing or touching the junction
- Esophageal invasion length of 2cm or less
- Clinical cancer stage CT2-4aN0-3M0 by abdominal contrast-enhanced CT or MRI
- Blood tests meeting specified hemoglobin, neutrophil, platelet, liver and kidney function levels
- Signed informed consent obtained
You will not qualify if you...
- Prior anti-cancer treatment before surgery
- Multiple malignant tumors in the stomach
- Suspicious lymph node metastasis in middle or upper mediastinum
- History of upper abdominal surgery (except laparoscopic cholecystectomy)
- Pregnant or breastfeeding women
- Uncontrolled epilepsy, central nervous system disease, or mental disorder
- Bulky N2 lymph node status
- Emergency surgery cases
- Severe heart disease
- Cerebral infarction or hemorrhage within past 6 months
- Organ transplant recipients requiring immunosuppressive therapy
- Other malignancies diagnosed within 5 years (except cured dermoid cancer and cervical cancer)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here